Clinical trials: sponsored by Henan Cancer Hospital
HER2 Positive Metastatic Breast Cancer
A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer
Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors.This study is a single-arm, prospective, open label clinical study of pyrotinib plus capecitabine as the Therapy of brain metastases from…
- Trial name
- NCT03691051
- Testing
- Pyrotinib plus Capecitabine
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Henan Cancer Hospital
HER2 Positive Metastatic Breast Cancer
Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.
This study plans to explore the efficacy and safety of chemotherapy combined with inetetamab and PD-1 inhibitors in HER2 positive advanced breast cancer who failed to receive trastuzumab and TKIs, and explore the dominant…
- Trial name
- NCT04681287
- Testing
- inetetamab and PD-1 inhibitor combined with chemotherapy.
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Henan Cancer Hospital
Bone and Soft Tissue Tumors, Clinical Features
Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors
It is planned to prospectively collect, collate and report real-world clinical data of BSTS patients treated in our hospital in the next ten years to evaluate the changes in clinical characteristics, treatment patterns and…
- Trial name
- NCT05468970
- Testing
- NO Intervention
- Where
- China
- Volunteers
- 6,000 people
- Sponsor
- Henan Cancer Hospital
Peripheral T Cell Lymphoma
Go-CHOP as the Frontline Therapy for PTCL
This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in Combination with CHOP as the front-line Treatment for Participants with Peripheral T-cell Lymphomas (PTCL).
- Trial name
- NCT05963347
- Testing
- Golidocitinib, CHOP Regimen
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Henan Cancer Hospital
Effectiveness, Sexuality
Lenvatinib for Advanced Bone and Soft Tissue Sarcoma
A total of 60 patients with metastatic/surgically unresectable bone and soft tissue sarcomas who had previously received multi-target TKI therapy and failed were enrolled to evaluate the efficacy and safety.
- Trial name
- NCT05617859
- Testing
- Lenvatinib mesylate capsule
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Squamous Cell Carcinoma of the Skin
Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin
This study intends to conduct a single-arm, prospective and open clinical study, using carrellizumab combined with albumin-binding paclitaxel regimen for first-line treatment of squamous cell carcinoma of the skin, including 24…
- Trial name
- NCT05886140
- Testing
- Carrilizumab with albumin-binding paclitaxel
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Henan Cancer Hospital
Cancer Pain, Real-world Study
Real World Study of Oxycodone Sustained-release Tablets for Patients With Moderate to Severe Cancer Pain
The goal of this real world study is to observe the efficacy and safety of Oxycodone Hydrochloride Sustained-release Tablets in the treatment of moderate to severe cancer pain participants in real clinical practice.
- Conditions
- Cancer Pain, Real-world Study, Oxycodone
- Trial name
- NCT05962294
- Where
- China
- Volunteers
- 916 people
- Sponsor
- Henan Cancer Hospital
Extensive Disease Small Cell Lung Cancer
Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC
Small cell lung cancer (SCLC) accounts for 10-15% of lung cancer. More than 70% of SCLC patients are diagnosed with advanced stage (ED-SCLC) at diagnosis.
- Trial name
- NCT04055792
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Henan Cancer Hospital
Peripheral T Cell Lymphoma
Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma
This is a non-randomized, open-label, Phase 1b clinical study to evaluate the safety, tolerability and anti-tumor efficacy of SHR0302 as monotherapy in patients with relapsed/refractory peripheral T/NK cell lymphoma.
- Trial name
- NCT05900089
- Testing
- SHR0302
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Metastatic Breast Cancer
Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer
The main purpose of this study was to observe the efficacy and safety of treatment with pyrotinib and CDK4/6 inhibitor SHR6390 for HER2-positive metastatic breast cancer.
- Trial name
- DAP-Her-01 (NCT04293276)
- Testing
- Pyrotinib, SHR6390
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Henan Cancer Hospital
Soft Tissue Sarcoma
Anrotinib Hydrochloride Combined With Adriamycin for Neoadjuvant Treatment of High-grade Soft Tissue Sarcoma
This is an investigator-initiated, single-arm, single-center, prospective clinical study with an estimated 58 patients enrolled to explore the efficacy and safety of anrotinib hydrochloride in combination with doxorubicin and…
- Trial name
- NCT05747521
- Testing
- Anrotinib hydrochloride combined with adriamycin
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Henan Cancer Hospital
Hydroxychloroquine, Gemcitabine
Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer
To evaluate the efficacy and safety of hydroxychloroquine (600mgBID) combined with gemcitabine (1000mg/m2,d1,8) in the third-line and above treatment of advanced NSCLC.
- Conditions
- Hydroxychloroquine, Gemcitabine, Lung Neoplasms
- Trial name
- NCT05647330
- Testing
- Hydroxychloroquine Combined With Gemcitabine
- Volunteers
- 55 people
- Sponsor
- Henan Cancer Hospital
Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy
This is a a phase 1, open label study to assess the safety and efficacy of ThisCART19 (Allogeneic CAR-T targeting CD19) in adult patients with B cell malignancies after failure of autologous chimeric antigen receptor T…
- Trial name
- NCT05640713
- Testing
- ThisCART19A, Fludarabine Pill, Cyclophosphamide
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Henan Cancer Hospital
HER2 Positive Breast Cancer
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.
Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors.This study is a single-arm, prospective, open label clinical study for evaluating the efficacy and safety of neoadjuvant pyrotinib and…
- Trial name
- NCT03735966
- Testing
- Pyrotinib plus trastuzumab and docetaxel and carboplatin
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Henan Cancer Hospital
Early Breast Cancer
GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel
Taxane-induced peripheral neuropathy (TIPN) caused by albumin-bound paclitaxel is a dose-limiting toxicity. The main symptoms of discomfort are numbness, tingling, and burning sensations in the glove-sock-like distribution of the…
- Trial name
- NCT04538833
- Testing
- monosialic gangliosides
- Where
- China
- Sponsor
- Henan Cancer Hospital
Gastric Cancer, Gastroesophageal-junction Cancer
Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes
Abstract Study title: Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on…
- Trial name
- NCT05608785
- Testing
- IBI315, Oxaliplatin, Capecitabine
- Volunteers
- 45 people
- Sponsor
- Henan Cancer Hospital
Advanced Gastric Adenocarcinoma
A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab
A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab
- Trial name
- NCT05583383
- Testing
- camrelizumab
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Henan Cancer Hospital
Esophagus Cancer
Neoadjuvant Chemotherapy Compared With Surgery for Esophageal Carcinoma
Most ESCC received NAC in China without supportive evidence from local RCTs. The negative conclusion about NAC originated from Western countries in the 1990s.
- Trial name
- NCT05569668
- Testing
- Paclitaxel- and platinum-based chemotherapy
- Where
- China
- Volunteers
- 826 people
- Sponsor
- Henan Cancer Hospital
Esophageal Neoplasm
Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma
The effect of neo-adjuvant chemotherapy on survival of patients with thoracic esophageal squamous cell carcinomas remains the most controversial part of neo-adjuvant therapy for esophageal carcinomas.
- Trial name
- NCT02395705
- Testing
- cisplatin and paclitaxel
- Where
- 9 sites in China
- Volunteers
- 528 people
- Sponsor
- Henan Cancer Hospital
Esophageal Cancer, Surgery
Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
The effect of neo-adjuvant immunochemotherapy on survival of patients with thoracic esophageal squamous cell carcinomas remains unknown.
- Conditions
- Esophageal Cancer, Surgery, Neoadjuvant Treatment, Survival
- Trial name
- NCT04280822
- Testing
- Neoadjuvant immunochemotherapy
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Henan Cancer Hospital